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Both leptin and vascular endothelial growth factor (VEGF) are growth and angiogenic cytokines that are upregulated in different types of
cancer and have been implicated in neoplastic progression. Here we investigated the molecular mechanism by which leptin and VEGF
expression are regulated in colon cancer by epidermal growth factor (EGF). In colon cancer cell line HT-29, EGF induced the binding of
signal transducer and activator transcription 3 (STAT3) to STAT3 consensus motifs within the VEGF and leptin promoters and stimulated
leptin and VEGF mRNA and protein synthesis. All these EGF effects were significantly blocked when HT-29 cells were treated with an
inhibitor of the phosphoinositide 3-kinase (PI3K) pathway, LY294002, or with small interfering RNA (siRNA) targeting STAT3. Thus, our
study identified the EGF/PI3K/STAT3 signaling as an essential pathway regulating VEGF and leptin expression in EGF-responsive colon
cancer cells. This suggests that STAT3 pathways might constitute attractive pharmaceutical targets in colon cancer patients where anti-
EGF receptor drugs are ineffective.
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DOI: 10.1002/jcp.21843Neoangiogenesis is a critical step for tumor growth and
metastatic spread (Folkman, 1971). New blood vessels
formation depends on the balance between positive and
negative regulators and is induced when factors that promote
angiogenesis are upregulated or those that inhibit angiogenesis
are down-regulated (Ferrara and Kerbel, 2005).
Vascular endothelial growth factor (VEGF) plays a major role
in tumor angiogenesis and its expression is inversely correlated
with patient survival in many human cancers, including colon
carcinomas (Logan-Collins et al., 2008; Zafirellis et al., 2008).
VEGF expression is regulated by various signaling pathways
induced by external stimuli (e.g., hypoxia, hormones, cytokines)
and may depend on the cellular context (e.g., the presence of
activated oncogenes) (Xu et al., 2005). Epidermal growth factor
(EGF) receptor (EGFR) signaling pathway is commonly
activated in colorectal cancer and has been investigated as a
target for cancer therapy (Mendelsohn and Baselga, 2000).
After ligand (EGF, transforming growth factor) binding to
EGFR, a cascade of downstream signaling is activated, including
activation of the Ras-MAP kinase and phosphoinositide 3-kinase
(PI3K)/Akt pathways (Mendelsohn and Baselga, 2000).
Moreover, in several cell lines, EGF as well as abnormal
activation of EGFR signaling pathways induces VEGF expression
(Maity et al., 2000; Zhong et al., 2000). Conversely, EGFR
inhibition can decrease VEGF expression, and consequently
angiogenesis, in many tumor types (Ciardiello and Tortora,
2001; Pore et al., 2006).
A less well-known factor with a strong neoangiogenic activity
is leptin (Cao et al., 2001; Anagnostoulis et al., 2008). Leptin is a
pleiotropic hormone whose major role is to regulate food
intake and energy balance via hypothalamic effects. Leptin also
affects many peripheral organs, behaving as a mitogen, survival
factor, metabolic regulator, or angiogenic factor (Wauters 2 0 0 9 W I L E Y - L I S S , I N C .et al., 2000; Cao et al., 2001; Misztal-Dethloff et al., 2004;
Gonzalez et al., 2006). Furthermore, there is evidence that
leptin promotes neoplastic processes in different cell types
(Garofalo et al., 2006; Housa et al., 2006). In colorectal cancer,
leptin can promote proliferation and invasiveness, and inhibit
apoptosis (Attoub et al., 2000; Aparicio et al., 2004; Amemori
et al., 2007; Jaffe and Schwartz, 2008). In addition, human
colorectal cancers have been shown to overexpress leptin as
well the leptin receptor (ObR) (Koda et al., 2007).
The VEGF and leptin gene promoters contain several
regulatory motif as ERE, CRE, SP-1, AP-2, HRE, and SRE
(STAT3-responsive element) (Finkenzeller et al., 1997; Mason
et al., 1998; Brenneisen et al., 2003). STAT3 is a transcription
factor activated through phosphorylation on a conserved
tyrosine residue (Tyr705), leading to STAT3 dimerization,
nuclear translocation and DNA binding to specific consensus
sequence TT(N4/5)AA (Seidel et al., 1995; Frank, 2007). STAT3
has been identified as a major regulator of VEGF expression in
glioblastoma and prostate cancer (Niu et al., 2002; Wei et al.,
2003). VEGF induction by various oncogenic growth stimuli,
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interruption of STAT3 signaling with dominant-negative STAT3
protein or STAT3 antisense nucleotide (Wei et al., 2003; Xu
et al., 2005).
Recently data demonstrated that STAT3 is involved in
colorectal cancer cells growth, survival, invasion, and migration
(Klampfer, 2008), through upregulation of various genes,
including VEGF (Xiong et al., 2008). However, the role of STAT3
in VEGF or leptin expression in colorectal cancer has never
been assessed.
Because the growth of colorectal cancer cells can be
regulated by the EGF/STAT3 pathway (Alvarez et al., 2006;
Vigneron et al., 2008), we tested if this pathway can be involved
in the activation of two angiogenic factors, VEGF and leptin.
Here we demonstrated that in colorectal cancer cell line
HT-29, EGF-induced leptin and VEGF expression is mediated by
the recruitment of STAT3 to SRE motif in both VEGF and leptin
gene promoters. EGF effects on VEGF and leptin expression
were significantly blocked with small interfering RNA (siRNA)
targeting STAT3.
Materials and Methods
Cell culture and treatments
HT-29 cells were grown in GIBCOTM Leibovitz’s L-15 Medium
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine
serum (FBS), 100 U/mL penicillin, and 50mg/mL streptomycin.
A total of 70% confluent cells were synchronized in serum-free
medium (SFM) for 24 h and then stimulated with 10 ng/ml EGF
(R&D Systems, Minneapolis, MN) for 24 h, with or without a 2 h
pre-treatment of PI3K inhibitor LY294002 (Calbiochem, San
Diego, CA) at 50mM.
Quantitative real-time-PCR (qRT-PCR)
HT-29 cells were treated, as described above, or left untreated.
Total cellular RNA was isolated using the RNeasy Mini Kit (Qiagen,
Inc., Valencia, CA). A total of 5mg of RNA was reverse transcribed
using the High-Capacity cDNA Archive (Applied Biosystems,
Foster City, CA) according to the manufacturer’s protocol. Five
microliters of the RT products were used to amplify leptin and
VEGF sequences using respectively the Hs00174877_m1 Lep and
the Hs00900054_m1 VEGF TaqMan Kit (Applied Biosystems),
following vendor’s instructions. To normalize qRT-PCR reactions,
parallel reactions were run on each sample for cyclophilin A.
Changes in the target mRNA content relative to cyclophilin A
mRNA were determined using a comparative CT method to
calculate changes in CT, and ultimately fold and percent change. An
average CT value for each RNA was obtained for replicate
reactions.
Leptin and VEGF detection by ELISA
A total of 3.6 107 HT-29 cells (or 1.8 107 for STAT3 siRNA)
were treated, as above described. Secreted VEGF and leptin were
measured in cell culture media using Human Quantikine ELISA Kits
(R&D Systems) with the lowest detection limit of 5 pg/ml for VEGF
and 7.8 pg/ml for leptin, intra-assay precision of <8.8% (VEGF)
and <4.9% (leptin), and inter-assay precision <9.2% (VEGF) and
<8.2% (leptin). All points were done in triplicate and the
experiments were repeated three times. All leptin and VEGF
concentrations were within the range of curve standard. Linear
regression analysis was performed to create the curve standard.
Western blotting (WB)
Cytoplasmic and nuclear protein extraction was performed using
NE-PER Extraction Reagents (Pierce Biotechnology, Inc.,
Rockford, IL). The expression of STAT3 was analyzed in 120mg of
cytoplasmic or nuclear cell lysates. The following antibodies were
used for WB: anti-STAT3 (C-20 X), anti-C23 (MS-3), andJOURNAL OF CELLULAR PHYSIOLOGYanti-GAPDH (8C2). All above antibody were purchased from Santa
Cruz (Santa Cruz Biotechnology, Santa Cruz, CA). Nuclear marker
nucleolin and cytoplasmic marker GAPDH were used as loading
controls.
Chromatin immunoprecipitation (ChIP)
ChIP was performed using the Chromatin Immunoprecipitation
Assay kit (Upstate, Temecula, CA), according to manufacturer’s
instructions. Soluble chromatin was immunoprecipitated with
STAT3 (C-20) pAb (Santa Cruz Biotechnology). The presence of
leptin and VEGF promoter domains containing STAT3 motifs in
immunoprecipitated DNA was identified by PCR using the
following primers: for leptin (region from 1892 to 1403)
forward 50-TTG TGG TCA GAC CAG TTT TCT-30, reverse
50-GTT TGG TAA TGC CCA AAA GCT-30, for VEGF (region
1041 from to 750) forward 50-CAG GAA CAA GGG CCT
CTG TCT-30, reverse 50-TGT CCC TCT GAC AAT GTG CCA
TC-30. The PCR conditions for leptin region were: 1 min at 948C,
1 min at 608C, 1 min at 728C; for VEGF region: 1 min 948C, 1 min at
648C, 1 min at 728C. The amplification of these regions was
analyzed after PCR 35 cycles.
Knockdown of STAT3 using small interfering RNA (siRNA)
STAT3 knockdowns were achieved using siRNAs (Dharmacon,
Inc., Lafayette, CO), according to manufacturer’s instructions.
Twenty-four hours following transfection, the cells were placed in
SFM for 24 h, then stimulated with EGF 10 ng/ml for 24 h or left
untreated. Non-specific siRNA (Dharmacon, Inc.) was used as a
negative control.
Results
EGF upregulates VEGF and leptin expression
Since it is known that EGF regulates tumor-associated
angiogenesis, we assessed EGF effects on the expression of
VEGF and leptin. First, we measured the effects of EGF on VEGF
and leptin mRNA levels. The treatment of HT-29 cells with EGF
for 24 h induced VEGF mRNA production by 1.4-fold (Fig. 1a).
Similarly, EGF stimulated leptin mRNA expression by 2.7-fold at
24 h relative to untreated cells (Fig. 1b). In parallel, EGF
increased the levels of secreted VEGF and leptin by 2.6- and
1.7-fold, respectively (Fig. 1c,d). These results suggested that
EGF upregulates VEGF and leptin at mRNA and protein levels.
EGF-induced STAT3 recruitment to VEGF
and leptin promoters
Analysis of the VEGF promoter revealed a putative binding site
for STAT3 at the 848 position (Niu et al., 2002). We also
identified two binding sites for STAT3 within the leptin
promoter at1715 and at1500 positions. Consequently, we
investigated whether STAT3 could mediate EGF effects on
VEGF and leptin expression in HT-29 colon cancer cell line.
We first examined the abundance of nuclear STAT3 in cells
treated with EGF (Fig. 2a). In untreated cells, STAT3 was
expressed in the nucleus at relatively low levels, while following
EGF stimulation, nuclear accumulation of STAT3 was
significantly increased (2.5-fold, relative to untreated cells); at
the same time, the cytoplasmic STAT3 levels remained
unchanged. Next, we assessed STAT3 binding to specific motifs
in the VEGF and leptin promoters (Fig. 2b). Our result suggested
that EGF increased STAT3 recruitment to both VEGF and leptin
promoters by three fold.
Silencing of STAT3 expression reduces VEGF and
leptin induction by EGF
To verify STAT3 involvement in EGF-induced VEGF and leptin
mRNA production, we silenced STAT3 expression using RNA
interference. The specific STAT3 siRNA down-regulated basal
Fig. 1. Leptin and VEGF mRNA and protein expression increases in response to EGF stimulation. a,b: The abundance of VEGF and leptin mRNA
were studied with qRT-PCR. HT-29 cells were synchronized in SFM for 24 h and then treated with 10 ng/ml EGF for 24 h or left untreated.
To normalize qRT-PCR reactions, parallel reactions were run on each sample for cyclophilin A. The graphs represent increase of VEGF and leptin
mRNA relative to SFM W SD. M, P < 0.05, control versus EGF. c,d: The abundance of VEGF and leptin proteins were determined by ELISA assay.
A total of 3.6 T 107 HT-29 cells were treated as previously described.
Fig. 2. EGF increases nuclear STAT-3 level and induces loading on the VEGF and leptin promoters. a: HT-29 cells at 70% confluence were
synchronizedinserum-freemedium(SFM)for24 handthenstimulatedwith10 ng/mlEGFfor24 h.TheexpressionofSTAT3wasassessedbyWBof
100mgcytoplasmicand120mgnuclearproteinsusingspecificAbs,asdescribedinMaterialandMethodsSection.GraphsrepresentrelativeSTAT3
expression level normalized to nuclear marker nucleolin and cytoplasmic marker GAPDH; Columns, mean; bars, SD; M, P < 0.05 basal versus EGF.
b: The binding of STAT-3 on both leptin and VEGF promoters was assessed by ChIP as described in Material and Methods Section. The graphs
represent the abundance of STAT3 on VEGF and leptin promoters under different conditions WSD; M, P < 0.05 basal versus EGF-treated Columns,
mean; bars, SD.
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effects on this protein (Fig. 3a). STAT3 knockdown reduced by
16% and 48% EGF-induced VEGF and leptin mRNA levels
respectively as well as down-regulated basal levels of both
factors (Fig. 3b). Similarly, STAT3 siRNA reduced EGF-induced
secreted VEGF and leptin proteins by 35% and 25%,
respectively (Fig. 3c).
PI3K pathway is involved in EGF-dependent VEGF
and leptin expression
The PI3K pathway can regulate VEGF and leptin expression in
different cancer cell lines (Maity et al., 2000; Pore et al., 2003;
Saxena et al., 2007). Using LY294002 inhibitor, we investigated
whether this pathway is required for VEGF and leptin
transcriptional regulation in HT-29 cells (Fig. 4c). Inhibition of
the PI-3K pathway down-regulated EGF-dependent VEGF and
leptin mRNA by 20%, LY294002 also blocked basal level of
VEGF mRNA by 70%, whereas basal level of leptin was not
affected (Fig. 4c).
Next, we studied whether inhibition of PI3K can affect
EGF-induced recruitment of STAT3 to the VEGF and leptin
promoters. First, we found that nuclear accumulation of STAT3Fig. 3. Knockdown of STAT3 reduces VEGF and leptin expression. a: The
achievedusingsiRNAsasdescribed inMaterialandMethodsSection.After2
with EGF 10 ng/ml for 24 h or left untreated. Non-specific siRNA was used
versus treated cells. b: The expression of VEGF and leptin mRNA in STAT
studiedbyqRT-PCR.c:Atotalof1.8 T 107cellsweretreatedasdescribedab
medium was determined by ELISA. Columns, mean; bars, SD; M or MM, P < 0
trasfectant.
JOURNAL OF CELLULAR PHYSIOLOGYwas inhibited by 30% under LY294002 treatment (Fig. 4a). This
was followed by reduced EGF-dependent binding of STAT3 to
the VEGF and leptin promoters by 30% and 50%, respectively
(Fig. 4b).
Discussion
Angiogenesis is an essential process for the growth of primary
tumor and metastasis formation and VEGF is a recognized
critical factor involved in this process (Folkman, 1971). Tumor
cells may produce VEGF in response to stimuli, such as
cytokines and growth factors, such as EGF, or under hypoxic
conditions. Angiogenesis might also be induced by leptin,
directly, or indirectly through upregulation of VEGF (Cao et al.,
2001; Misztal-Dethloff et al., 2004; Suganami et al., 2004;
Anagnostoulis et al., 2008). Here we studied the molecular
mechanism by which EGF can promote angiogenesis in
colorectal cancer cells, focusing on EGF-dependent activation
of pro-angiogenic factors, VEGF and leptin.
We found that in HT-29 colon cancer cell lines, VEGF and
leptin levels were upregulated under EGF stimulation. Using
qRT-PCR and ELISA assays, we documented increasedexpression of STAT3 was determined by WB. Stat3 knockdowns were
4 hfromtransfection,cellswereplaced inSFMfor24 hthenstimulated
as a negative control. Columns, mean; bars, SD; M, P < 0.05 SFM
3 siRNA transfectants treated for 24 h with EGF or left untreated was
ove.TheabundanceofsecretedleptinandVEGF(pg/ml) inconditioned
.05 basal versus siSTAT3 trasfectant or EGF versus EGF R siSTAT3
Fig. 4. EGF-induced VEGF and leptin expression is mediated by PI3K. a: HT-29 cells were treated for 24 h with 10 nM EGF for 24 h and/or 50mM
LY294002. The nuclear abundance of STAT3 was assessed by WB. b: The binding of STAT3 to VEGF and leptin promoter was determined by ChIP
as described in material and Methods Section. c: The abundance of VEGF and leptin mRNA was studied with qRT-PCR in HT-29 cells untreated
or treated with EGF, and/or LY294002. Columns, mean; bars, SD; M or MM, P < 0.05 basal versus LY-treated or EGF versus EGF R LY-treated.
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data are in agreement with the observation that in glioblastoma
and prostate cancer cells, EGF can induce VEGF expression
(Maity et al., 2000; Zhong et al., 2000). However, direct
mechanistic link between EGF and VEGF in colon cancer cells
has not been described until now. Moreover, to our knowledge,
our data provide the first mechanistic evidence on the role of
EGF in the control of leptin expression in cancer cells.
It is known that VEGF promoter contains binding sites for
STAT3. A recent study in mouse cerebral endothelial cells
identified STAT3-mediated VEGF expression induced by
ectopic decorin, a ligand for EGFR (Santra et al., 2008). The
leptin promoter also contains two potential sites for STAT3
localized at 1715 and 1500 in the promoter. While it is
known that STAT3 activation mediates many of the biological
effects of leptin (Catalano et al., 2009), there are not evidences
regarding STAT3 involvement in leptin gene transcription. Our
study demonstrated for the first time that EGF-induced leptin
and VEGF expression in colon cancer is mediated by and
requires STAT3. Specifically, our results suggested that STAT3
binds both VEGF and leptin promoters under EGF stimulation
in colon cancer cells and STAT3 down-regulation by
RNA-interference significantly suppressed both VEGF and
leptin expression.
Our previous study in cancer cells suggested that PI3K is
involved in leptin expression (Bartella et al., 2008). PI3K
involvement in leptin expression was also confirmed in other
cell models (Cong et al., 2007; Tong et al., 2008). The PI3K/
mTOR pathway has also been shown to play an important role
in VEGF regulation (Zhong et al., 2000; Laughner et al., 2001;
Kang et al., 2008). In agreement with these observations, we
found that PI-3K is required for leptin and VEGF expressionJOURNAL OF CELLULAR PHYSIOLOGYunder EGF treatment, especially for STAT3 recruitment to
both VEGF and leptin promoters, as demonstrated by ChIP
assay.
In summary, we demonstrated that in colorectal cancer cells,
EGF can upregulate the expression of two pro-angiogenic
factors, VEGF and leptin via the PI3K signaling pathway. We
report that the mechanism of this EGF-activity occurs at
transcriptional level and it is mediated by the recruitment of
STAT3 on VEGF and leptin promoters. The fact that EGF can
stimulate leptin expression in colon cancer suggest that leptin
and its receptor can become novel pharmaceutical targets in
colorectal cancer. In addition, STAT3, which appears to play a
major role in regulation of genes involved in angiogenesis might
serve as alternative target in colon cancer patients in which
anti-EGFR therapies are not effective.
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